» Articles » PMID: 16883008

Tissue Distribution of 18F-FDG-labeled Peripheral Hematopoietic Stem Cells After Intracoronary Administration in Patients with Myocardial Infarction

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2006 Aug 3
PMID 16883008
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Adult stem cell therapy is expected to improve left ventricular function in patients with myocardial infarction. Because of the low risk of arrhythmia and the maximal concentration at the target tissue, intracoronary infusion of stem cells is preferred. The aim of this study was to investigate the homing and tissue distribution of intracoronary injected peripheral hematopoietic stem cells labeled with 18F-FDG.

Methods: Seventeen patients with myocardial infarction were included as the intracoronary injection group (14 males, 3 females; age, 58 +/- 12 y). Three patients underwent intravenous stem cell injection as the intravenous injection group (3 males, 0 females; age, 50 +/- 20 y). After mobilization with granulocyte colony-stimulating factor (G-CSF), peripheral stem cells were collected by means of apheresis. 18F-FDG labeling of stem cells was performed for 40 min with gentle intermittent mixing at 37 degrees C. The mean labeling efficiency was 72% (range, 46%-95%), and 44.4-175 MBq (1.2-5 mCi) of 18F-FDG-labeled stem cells were injected via an intracoronary catheter after stenting in infarct-related arteries. PET/CT images were obtained with a 3-dimensional acquisition mode 2 h after intracoronary infusion.

Results: Two hours after intracoronary infusion, 1.5% (range, 0.2%-3.3%) of injected stem cells accumulated at the infarcted myocardium. Outside of the myocardium, spleen, liver, bladder, and bone marrow showed a high stem cell accumulation. The delayed image of a patient up to 20 h showed a prolonged residence of stem cells at the myocardium. Intravenous injection of stem cells showed a high initial lung uptake with no myocardial activity.

Conclusion: We have shown that 18F-FDG-labeled stem cell PET could be used to assess the tissue distribution and to measure the amount of stem cells at a target tissue. 18F-FDG-labeled stem cell PET can be used to measure and optimize the amount of stem cells injected.

Citing Articles

Bright ferritin for long-term MR imaging of human embryonic stem cells.

Zhuang K, Romagnuolo R, Sadikov Valdman T, Vollett K, Szulc D, Cheng H Stem Cell Res Ther. 2023; 14(1):330.

PMID: 37964388 PMC: 10647036. DOI: 10.1186/s13287-023-03565-4.


Recent clinical trials with stem cells to slow or reverse normal aging processes.

Garay R Front Aging. 2023; 4:1148926.

PMID: 37090485 PMC: 10116573. DOI: 10.3389/fragi.2023.1148926.


Case report: Directional infusion of peripheral blood stem cells into the necrotic zone in femoral heads through the medial circumflex femoral artery: A tracing study.

Mao Q, Shao W, Lv S, Tong P, He B Front Med (Lausanne). 2022; 9:945268.

PMID: 36059815 PMC: 9433798. DOI: 10.3389/fmed.2022.945268.


Systemically injected bone marrow mononuclear cells specifically home to axially vascularized tissue engineering constructs.

Eweida A, Flechtenmacher S, Sandberg E, Schulte M, Schmidt V, Kneser U PLoS One. 2022; 17(8):e0272697.

PMID: 35951604 PMC: 9371259. DOI: 10.1371/journal.pone.0272697.


Direct Cell Radiolabeling for Cell Tracking with PET and SPECT Imaging.

Gawne P, Man F, Blower P, T M de Rosales R Chem Rev. 2022; 122(11):10266-10318.

PMID: 35549242 PMC: 9185691. DOI: 10.1021/acs.chemrev.1c00767.